Clarification

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Clarification

A guest editorial in The Cancer Letter stated that “work has halted on ECOG-ACRIN Cancer Research Group’s landmark Tomosynthesis Mammographic Imaging Screening Trial.” (The Cancer Letter, April 10, 2020) The TMIST breast cancer screening trial is not suspended. TMIST formally remains an ongoing study under the NCI and Cancer Trials Support Unit. Active participation at this time is at the discretion of individual sites. Sites are making critical local operational decisions to help manage any potential influx of COVID-19 patients and maintain the safety of patients and staff. As a result, some sites have suspended non-urgent health care services, such as screening mammography, and research operations.

Correction

A COVID-19 Update on April 24 reported that The Association of American Cancer Institutes annual meeting has moved to a virtual format (The Cancer Letter, April 24, 2020). The Association of American Cancer Institutes’ Clinical Research Innovation (CRI) program has moved its July 7-8 annual meeting to a virtual format. The AACI annual meeting, which takes place Oct. 11-13 in Kansas City, MO, is still scheduled as an in-person meeting at this time.

Table of Contents

YOU MAY BE INTERESTED IN

As Ben Ho Park sees it, the mission of a cancer researcher doesn’t stop at the water’s edge. It follows that Park’s new role as director of Vanderbilt-Ingram Cancer Center is inseparable from his role as an executive of the Global Cancer Institute, a nonprofit that works with healthcare providers in low- and middle-income countries to improve survival rates for underserved cancer patients.

Login